Healthcare
Zevra Therapeutics, Inc.(ZVRA)
Live Price
Offline$12.90
+2.30% today
1Y Change
+40.56%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $590.00M
- Revenue Growth
- +350.9%
- EPS Growth
- +161.4%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zevra Therapeutics, Inc. (ZVRA) is a Healthcare stock with a market cap of $590.00M and listed on NASDAQ. The stock last traded around $12.90 and up 40.6% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +350.9%, EPS growth of +161.4%, a dividend yield of 0.0%. What stands out right now is revenue +350.9%, EPS +161.4%, free cash flow +96.5% with operating margin -59.1% and ROIC -24.6%. Valuation is more restrained than many high-expectation growth names at P/E 6.7 and price/sales 5.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ZVRA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+350.9% vs +7.6% peer median
Operating Margin
Below sector median
-59.1% vs +19.4% peer median
P/E
Below sector median
6.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +350.9% and EPS at +161.4%, with operating margin around -59.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +0.6% | -7.7% | +22.2% |
2026 Mar 9, 2026 | +2201.6% | +21.3% | +8.2% | +6.1% |
2025 Nov 5, 2025 | +50.0% | -9.7% | -6.7% | -14.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZVRA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
ZVRA Max Drawdown
-43.47%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ZVRA and SPY.
Company Overview
Zevra Therapeutics, Inc.
NASDAQ Global Select
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
- Leadership
- Neil F. McFarlane
- IPO Date
- Apr 16, 2015
- Employees
- 59
- Street Address
- 1180 Celebration Boulevard
- Mailing
- Celebration, FL, 34747
- Region
- Celebration, FL, US
- Reporting Currency
- USD
- Investor Line
- 321 939 3416
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 6.7
- EV/EBITDA
- 6.0
- Price/Sales
- 5.6
- Price/Book
- 3.6
Growth
- Revenue
- +350.9%
- EPS
- +161.4%
- Free Cash Flow
- +96.5%
Profitability
- Gross Margin
- 84.2%
- Operating Margin
- -59.1%
- Net Margin
- 78.2%
- ROE
- 74.6%
- ROIC
- -24.6%
Balance Sheet
- Debt/Equity
- 0.41
- Current Ratio
- 5.68
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.